Association of Kif11 and PCNA expression with clinical characteristics and selected biological markers of CCRCC
| Characteristic | n | Kif11 expression (%) | PCNA expression (%) | ||||||
| High | Low or none | χ2 | P value | High | Low or none | χ2 | P value | ||
| Age (years) | 0.245 | 0.621 | 0.200 | 0.655 | |||||
| ≤60 | 70 | 45 (64.29) | 25 (35.71) | 40 (57.14) | 30 (42.9) | ||||
| >60 | 73 | 44 (60.27) | 29 (39.73) | 39 (53.42) | 34 (46.6) | ||||
| Location | 0.632 | 0.426 | 0.110 | 0.740 | |||||
| Left | 76 | 45 (59.21) | 31 (40.79) | 41 (53.95) | 35 (46.1) | ||||
| Right | 67 | 44 (65.67) | 23 (34.33) | 38 (56.72) | 29 (43.3) | ||||
| Gender | 1.483 | 0.223 | 0.414 | 0.520 | |||||
| Male | 100 | 59 (59.00) | 41 (41.00) | 57 (57.00) | 43 (43.0) | ||||
| Female | 43 | 30 (69.77) | 13 (30.23) | 22 (51.16) | 21 (48.8) | ||||
| Tumour size (cm) | 2.483 | 0.115 | 1.526 | 0.217 | |||||
| ≤7 | 70 | 39 (55.71) | 31 (44.29) | 35 (50.00) | 35 (50.0) | ||||
| >7 | 73 | 50 (68.49) | 23 (31.51) | 44 (60.27) | 29 (39.7) | ||||
| Nuclear grade | 7.737 | 0.021 | 6.513 | 0.039 | |||||
| G1 | 52 | 25 (48.08) | 27 (51.92) | 22 (42.31) | 30 (57.69) | ||||
| G2 | 61 | 41 (67.21) | 20 (32.79) | 36 (59.02) | 25 (40.98) | ||||
| G3–4 | 30 | 23 (76.67) | 7 (23.33) | 21 (70.00) | 9 (30.00) | ||||
| TNM stage | 22.55 | <0.001 | 13.030 | 0.001 | |||||
| Ⅰ | 57 | 22 (38.60) | 35 (61.40) | 21 (36.84) | 36 (63.16) | ||||
| Ⅱ | 60 | 47 (78.33) | 13 (21.67) | 40 (66.67) | 20 (33.33) | ||||
| Ⅲ+Ⅳ | 26 | 20 (76.92) | 6 (23.08) | 18 (69.23) | 8 (30.77) | ||||
CCRCC, clear cell renal cell carcinoma; Kif11, kinesin family member 11; PCNA, proliferating cell nuclear antigen.